New York-based pharmaceutical giant Bristol-Myers Squibb has reportedly signed a deal worth $438 million with Reckitt Benckiser, a personal health products company based in the UK. According to reports, the deal will last for three years an includes an agreement to a $44 million option fee, giving Reckitt the option of buying Bristol-Myers brands at the end of the three years. The contract gives Bristol-Myers control over Reckitt manufacturing and, in turn, allows Reckitt to sell Bristol-Myers medicines throughout Latin America, especially Mexico and Brazil. Mexico and Brazil antitrust authorities may review the deal, however.
Featured News
Google Sues Alleged China-Based Hackers Over Widespread Phishing Scheme
Dec 22, 2025 by
CPI
Europe Moves to Clarify What Counts as Personal Data
Dec 22, 2025 by
CPI
Larry Ellison Offers $40 Billion Guarantee as Paramount Renews Bid for Warner Bros
Dec 22, 2025 by
CPI
Google Sues Texas Firm Over Alleged Massive Scraping of Search Data
Dec 22, 2025 by
CPI
Italy Fines Apple Nearly 100 Million Euros Over App Store Practices
Dec 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi